Tandem Meetings 2023

Laura M. Healy

March 1, 2023

Iomab-B plus RIC enables ASCT in a population of AML patients who are not typically eligible for transplant, a phase 3 study suggests.

Laura M. Healy

February 27, 2023

Reinfusion with the CAR T-cell therapy tisagenlecleucel does not produce durable remissions in children and AYAs with B-ALL, a study suggests.

Laura M. Healy

February 22, 2023

Pano/GBM is safe and effective as conditioning before ASCT in patients with high-risk or relapsed/refractory multiple myeloma, a study suggests.

Laura M. Healy

February 21, 2023

Zamtocabtagene autoleucel produced responses in patients with relapsed/refractory diffuse large B-cell lymphoma in a phase 2 trial.

Next post in Tandem Meetings 2023

Want to read more?